Working to Eradicate Gynecologic Cancers

George Larry Maxwell, MD

Chairman, Department of Obstetrics and Gynecology
Inova Fairfax Hospital
3300 Gallows Road
Falls Church, VA
USA 22042

Papers:
11 - Focused Plenary Molecular profiling of tumors from stage I versus stage III/IV cancer patients: a prediction signature for metastasis in Gynecologic Oncology Group 8024 41 - Featured Poster The impact and interaction of preoperative disease burden, complex surgery, and residual disease in patients with advanced stage ovarian cancer and the effect on on patient survival: A GOG 182 analysis 43 - Featured Poster Identification of candidate circulating cisplatin resistance biomarkers from epithelial ovarian carcinoma cell secretomes 49 - Featured Poster Pathogenesis of ARID1A-driven gynecologic cancer 52 - Featured Poster Pharmacologic inhibition of the DNA damage response kinases ATR (ataxia telangiectasia and rad3 related) and ATM (ataxia telangiectasia mutated) broadly sensitizes diverse subtypes of gynecologic cancer cells to ionizing radiation 60 - Scientific Plenary Predictive model for preoperative determination of microscopic residual disease at the time of primary cytoreduction in patients with advanced-stage epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) 182 analysis 98 - Featured Poster Phase I trial results of a folate receptor alpha-directed cancer vaccine (E39) in ovarian and endometrial cancer patients to prevent recurrence 168 - Poster Session A A dose-dense paclitaxel and carboplatin regimen is highly active in the treatment of recurrent and advanced endometrial cancer 229 - Poster Session A Subcellular localization of AT-rich interactive domain1A protein expression is associated with survival in epithelial ovarian and peritoneal carcinoma 237 - Poster Session A Clinicopathologic benchmark for prognostic modeling of advanced epithelial ovarian cancer long-term survival: a Gynecologic Oncology Group (GOG) analysis 269 - Poster Session A Enhanced gynecologic cancer cell killing through pharmacologic inhibition of the ataxia telangiectasia and Rad3-related kinase 273 - Poster Session A Progestin and vitamin D suppress growth of ovarian cancer in vitro and in vivo 282 - Poster Session A Ovarian cancers with nuclear special AT-rich sequence-binding protein 1 and cytoplasmic AT-rich interactive domain-containing protein 1A are rare, drug-resistant, and deadly 295 - Poster Session A Curated Ovarian Database-derived identification of genes predicting survival in primary serous epithelial ovarian cancer 306 - Poster Session A Pharmacologic inhibition of polo-like kinase 1 enhances paclitaxel-based cell killing in taxol-resistant ovarian cancer cells 334 - Poster Session A Proteomic profiling of stage I endometrial cancers: a signature of early-stage recurrence in GOG 8016 337 - Poster Session A Proteomics of endometrial carcinogenesis: identification of candidates underlying disease pathogenesis 525 - Poster Session B Correlation of survival-stratified proteomic and curated gene data reveal a three protein biomarker panel that predicts long-term survival of patients with primary epithelial ovarian cancer 526 - Poster Session B Diminished survival of separated, divorced, or widowed uterine cancer patients: a potential focus for survivorship programs